- Home
- NVS
NVS
Novartis AG
as of 12-17-2025 3:51pm EST
$135.30
+$0.27
+0.20%
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Chart Type:
Time Range:
| Founded: | 1895 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 254.8B | IPO Year: | 1991 |
| Target Price: | $118.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 7.30 | EPS Growth: | -14.91 |
| 52 Week Low/High: | $96.06 - $136.66 | Next Earning Date: | 01-30-2026 |
| Revenue: | $56,372,000,000 | Revenue Growth: | 12.88% |
| Revenue Growth (this year): | 9.33% | Revenue Growth (next year): | 2.75% |
Latest Novartis AG News
NVS Breaking Stock News: Dive into NVS Ticker-Specific Updates for Smart Investing
Insider Monkey
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Has Novartis’ 24.5% Surge Left Further Upside After Strong Pipeline and Cash Flow Gains?
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Novartis Breaks Ground on North Carolina Manufacturing Hub
📊
AI Sentiment
Positive
7/10
Insider Monkey
Novartis (NVS) Enters $1.7 Billion Development Deal, Says Report
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Novartis breaks ground on flagship manufacturing hub in North Carolina
📈
AI Sentiment
Highly Positive
8/10
Pharmaceutical Technology
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
📈
AI Sentiment
Highly Positive
8/10
Compare NVS vs Leading Stocks
See how NVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVS Novartis AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.